Celgene Collaborates with Vividion for US$101 M Upfront to Target Tough-to-Drug Proteins
By Natasha Piper
Pharma Deals Review: Vol 2018 Issue 3 (Table of Contents)
Published: 22 Mar-2018
DOI: 10.3833/pdr.v2018.i3.2316 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Celgene has announced a four-year strategic research collaboration with Vividion Therapeutics to utilise its platform, which allows protein-drug interactions to be measured directly within native biological systems, to identify new targets for a range of oncology, inflammatory and neurodegenerative disease...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS